Complix has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co, to develop Cell Penetrating Alphabodies (CPABs), able to cross the blood brain barrier, for the improved treatment of diseases of the central nervous system (CNS).
Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, today announced that it has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co., one of China's leading CNS companies, to develop Cell Penetrating Alphabodies (CPABs)